

Hans Tjärnblom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8194984/publications.pdf>

Version: 2024-02-01

109
papers

5,301
citations

147801

31
h-index

91884

69
g-index

116
all docs

116
docs citations

116
times ranked

4497
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1315-1325.e4.	4.4	9
2	Food Avoidance and Restriction in Irritable Bowel Syndrome: Relevance for Symptoms, Quality of Life and Nutrient Intake. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1290-1298.e4.	4.4	31
3	Chronic Constipation as a Risk Factor for Colorectal Cancer: Results From a Nationwide, Case-Control Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1867-1876.e2.	4.4	15
4	Global Prevalence and Impact of Rumination Syndrome. <i>Gastroenterology</i> , 2022, 162, 731-742.e9.	1.3	12
5	Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome. <i>Nutrients</i> , 2022, 14, 397.	4.1	13
6	The Role of Carbohydrates in Irritable Bowel Syndrome: Protocol for a Randomized Controlled Trial Comparing Three Different Treatment Options. <i>JMIR Research Protocols</i> , 2022, 11, e31413.	1.0	0
7	Letter in response to Black et al. (2020). <i>Neurogastroenterology and Motility</i> , 2022, 34, e14329.	3.0	1
8	Global prevalence and burden of meal-related abdominal pain. <i>BMC Medicine</i> , 2022, 20, 71.	5.5	11
9	Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with Irritable Bowel Syndrome. <i>BMC Gastroenterology</i> , 2022, 22, 73.	2.0	4
10	Evidence-Based and Emerging Dietary Approaches to Upper Disorders of Gut-Brain Interaction. <i>American Journal of Gastroenterology</i> , 2022, 117, 965-972.	0.4	10
11	Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14390.	3.0	4
12	Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1501-1511.	3.7	12
13	Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 160-161.	3.7	0
14	European guidelines on functional bowel disorders with diarrhoea: United European Gastroenterology (UEG) and European Society for neurogastroenterology and motility (ESNM) statements and recommendations. <i>United European Gastroenterology Journal</i> , 2022, 10, 615-616.	3.8	1
15	Disorders of gut-brain interaction: Highly prevalent and burdensome yet under-taught within medical education. <i>United European Gastroenterology Journal</i> , 2022, 10, 736-744.	3.8	10
16	Irritable bowel syndrome: Factors of importance for disease-specific quality of life. <i>United European Gastroenterology Journal</i> , 2022, 10, 754-764.	3.8	8
17	Prevalence and Progression of Recurrent Abdominal Pain, From Early Childhood to Adolescence. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 930-938.e8.	4.4	19
18	Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility Spectrum Disorders or Hypermobility Ehlers-Danlos Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 277-287.e3.	4.4	29

#	ARTICLE	IF	CITATIONS
19	Online Education Is Non-Inferior to Group Education for Irritable Bowel Syndrome: A Randomized Trial and Patient Preference Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 743-751.e1.	4.4	5
20	Association between pain sensitivity and gray matter properties in the sensorimotor network in women with irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14027.	3.0	8
21	Association between <i>Brachyspira</i> and irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2021, 70, 1117-1129.	12.1	31
22	A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α -galactosidase on gastrointestinal symptoms in irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14094.	3.0	4
23	A novel stepwise integrative analysis pipeline reveals distinct microbiota-host interactions and link to symptoms in irritable bowel syndrome. <i>Scientific Reports</i> , 2021, 11, 5521.	3.3	4
24	Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome. <i>Microbiome</i> , 2021, 9, 74.	11.1	25
25	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2021, 9, 307-331.	3.8	62
26	Central sensitization and severity of gastrointestinal symptoms in irritable bowel syndrome, chronic pain syndromes, and inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14156.	3.0	18
27	A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome. <i>Cells</i> , 2021, 10, 1459.	4.1	23
28	Reply: The key to success: Targeting enzymes to their dietary counterpart. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14203.	3.0	0
29	Allergy-related diseases in childhood and risk for abdominal pain-related functional gastrointestinal disorders at 16 years: a birth cohort study. <i>BMC Medicine</i> , 2021, 19, 214.	5.5	8
30	Psychopharmacologic Therapies for Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 655-669.	2.2	7
31	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14238.	3.0	21
32	Gluten and fructan intake and their associations with gastrointestinal symptoms in irritable bowel syndrome: A food diary study. <i>Clinical Nutrition</i> , 2021, 40, 5365-5372.	5.0	16
33	Cumulative Effect of Psychological Alterations on Gastrointestinal Symptom Severity in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 769-779.	0.4	22
34	Habitual FODMAP Intake in Relation to Symptom Severity and Pattern in Patients with Irritable Bowel Syndrome. <i>Nutrients</i> , 2021, 13, 27.	4.1	11
35	Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. <i>United European Gastroenterology Journal</i> , 2021, 9, 1178-1188.	3.8	18
36	Changes in serum and urinary metabolomic profile after a dietary intervention in patients with irritable bowel syndrome. <i>PLoS ONE</i> , 2021, 16, e0257331.	2.5	6

#	ARTICLE	IF	CITATIONS
37	The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome. <i>Nutrients</i> , 2021, 13, 3836.	4.1	17
38	OTH-5â€œ...Functional gastrointestinal disorders and associated health impairment in individuals with coeliac disease. , 2021, , .		0
39	Altered Structural Covariance of Insula, Cerebellum and Prefrontal Cortex Is Associated with Somatic Symptom Levels in Irritable Bowel Syndrome (IBS). <i>Brain Sciences</i> , 2021, 11, 1580.	2.3	4
40	Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. <i>Gastroenterology</i> , 2020, 158, 1262-1273.e3.	1.3	249
41	Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 874-884.	1.9	24
42	Adherence to diet low in fermentable carbohydrates and traditional diet for irritable bowel syndrome. <i>Nutrition</i> , 2020, 73, 110719.	2.4	12
43	An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 39-46.	3.0	148
44	Traditional treatments for irritable bowel syndrome: the state of our knowledge. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 94-95.	8.1	0
45	The diagnostic value of a change in bowel habit for colorectal cancer within different age groups. <i>United European Gastroenterology Journal</i> , 2020, 8, 211-219.	3.8	4
46	Functional gastrointestinal disorders are increased in joint hypermobilityâ€œrelated disorders with concomitant postural orthostatic tachycardia syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13975.	3.0	19
47	Patient-Specific Stressâ€œAbdominal Pain Interaction in Irritable Bowel Syndrome: An Exploratory Experience Sampling Method Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00209.	2.5	10
48	Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, doubleâ€œblind, placeboâ€œcontrolled study. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13920.	3.0	32
49	A survey on the impact of the COVIDâ€œ19 pandemic on motility and functional investigations in Europe and considerations for recommencing activities in the early recovery phase. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13926.	3.0	14
50	Associations among neurophysiology measures in irritable bowel syndrome (IBS) and their relevance for IBS symptoms. <i>Scientific Reports</i> , 2020, 10, 9794.	3.3	14
51	Resting state functional connectivity of the pain matrix and default mode network in irritable bowel syndrome: a graph theoretical analysis. <i>Scientific Reports</i> , 2020, 10, 11015.	3.3	17
52	Foodâ€œsymptom diaries can generate personalized lifestyle advice for managing gastrointestinal symptoms: A pilot study. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13820.	3.0	2
53	Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome. <i>Scientific Reports</i> , 2020, 10, 593.	3.3	37
54	Mortality Risk in Irritable Bowel Syndrome: Results From a Nationwide Prospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2020, 115, 746-755.	0.4	17

#	ARTICLE	IF	CITATIONS
55	Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): results from two separate surveys of HCPs and patients with IBS-D. <i>BMC Gastroenterology</i> , 2020, 20, 127.	2.0	3
56	Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 878-886.	4.4	93
57	Cumulative Effects of Psychologic Distress, Visceral Hypersensitivity, and Abnormal Transit on Patient-reported Outcomes in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2019, 157, 391-402.e2.	1.3	81
58	Colonic mast cell numbers, symptom profile, and mucosal expression of elements of the epithelial barrier in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13701.	3.0	10
59	Effects of the long-term storage of human fecal microbiota samples collected in RNAlater. <i>Scientific Reports</i> , 2019, 9, 601.	3.3	36
60	Anxiety and depression in irritable bowel syndrome: Exploring the interaction with other symptoms and pathophysiology using multivariate analyses. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13619.	3.0	66
61	Relations between food intake, psychological distress, and gastrointestinal symptoms: A diary study. <i>United European Gastroenterology Journal</i> , 2019, 7, 965-973.	3.8	19
62	Visceral sensitivity remains stable over time in patients with irritable bowel syndrome, but with individual fluctuations. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13603.	3.0	8
63	Evidence for an association of gut microbial Clostridia with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis. <i>Microbiome</i> , 2019, 7, 45.	11.1	83
64	Fasting breath H ₂ and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome. <i>PLoS ONE</i> , 2019, 14, e0214273.	2.5	12
65	Within- and Between-Subject Variation in Dietary Intake of Fermentable Oligo-, Di-, Monosaccharides, and Polyols Among Patients with Irritable Bowel Syndrome. <i>Current Developments in Nutrition</i> , 2019, 3, nzy101.	0.3	13
66	Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: A population-based study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13483.	3.0	28
67	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1002-1004.	4.4	0
68	Development of Irritable Bowel Syndrome Features Over a 5-year Period. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1244-1251.e1.	4.4	18
69	Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 252-262.	8.1	199
70	Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. <i>Gastroenterology</i> , 2018, 154, 1140-1171.e1.	1.3	247
71	Functional Dyspepsia and Severity of Psychologic Symptoms Associate With Postprandial Symptoms in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1745-1753.e1.	4.4	21
72	Factor Analysis Defines Distinct Upper and Lower Gastrointestinal Symptom Groups Compatible With Rome IV Criteria in a Population-based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1252-1259.e5.	4.4	18

#	ARTICLE	IF	CITATIONS
73	Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. <i>Gut</i> , 2018, 67, 872-881.	12.1	176
74	Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. <i>Gut</i> , 2018, 67, 255-262.	12.1	186
75	Relationships between psychological state, abuse, somatization and visceral pain sensitivity in irritable bowel syndrome. <i>United European Gastroenterology Journal</i> , 2018, 6, 300-309.	3.8	20
76	The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. <i>American Journal of Gastroenterology</i> , 2018, 113, 86-96.	0.4	138
77	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. <i>Gut</i> , 2018, 67, 1425-1433.	12.1	27
78	Oesophageal symptoms are common and associated with other functional gastrointestinal disorders (FGIDs) in an English-speaking Western population. <i>United European Gastroenterology Journal</i> , 2018, 6, 1461-1469.	3.8	10
79	Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders. <i>Current Gastroenterology Reports</i> , 2018, 20, 58.	2.5	35
80	Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects. <i>Scientific Reports</i> , 2018, 8, 16821.	3.3	10
81	Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. <i>American Journal of Gastroenterology</i> , 2018, 113, 1540-1549.	0.4	127
82	Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13468.	3.0	15
83	Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: Results from patient and healthcare professional surveys. <i>United European Gastroenterology Journal</i> , 2018, 6, 1417-1427.	3.8	22
84	Pre- and perinatal stress and irritable bowel syndrome in young adults – A nationwide register-based cohort study. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13436.	3.0	11
85	Funding for gastrointestinal disease research in the European Union. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 593-595.	8.1	9
86	How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. <i>American Journal of Gastroenterology</i> , 2018, 113, 1017-1025.	0.4	90
87	Management of the multiple symptoms of irritable bowel syndrome. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 112-122.	8.1	54
88	Coping Skills Are Associated With Gastrointestinal Symptom Severity and Somatization in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1565-1571.e3.	4.4	27
89	Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, 111-123.e8.	1.3	470
90	Centrally Targeted Pharmacotherapy for Chronic Abdominal Pain: Understanding and Management. <i>Handbook of Experimental Pharmacology</i> , 2016, 239, 417-440.	1.8	7

#	ARTICLE	IF	CITATIONS
91	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1222-1223.	4.4	0
92	Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2016, 111, 1165-1176.	0.4	86
93	Treatment of gastrointestinal autonomic neuropathy. <i>Diabetologia</i> , 2016, 59, 409-413.	6.3	14
94	Reply. <i>Gastroenterology</i> , 2016, 150, 1047-1048.	1.3	0
95	Lactulose Challenge Determines Visceral Sensitivity and Severity of Symptoms in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 226-233.e3.	4.4	38
96	Depression and Somatization Are Associated With Increased Postprandial Symptoms in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 150, 866-874.	1.3	71
97	In search for a disease-modifying treatment in irritable bowel syndrome. <i>Gut</i> , 2016, 65, 2-3.	12.1	6
98	Practical management of irritable bowel syndrome: a clinical review. <i>Minerva Gastroenterologica E Dietologica</i> , 2016, 62, 30-48.	2.2	10
99	Authors'™ response: Bile acids are important in the pathophysiology of IBS. <i>Gut</i> , 2015, 64, 851.2-852.	12.1	1
100	Nurse-Administered, Gut-Directed Hypnotherapy in IBS: Efficacy and Factors Predicting a Positive Response. <i>American Journal of Clinical Hypnosis</i> , 2015, 58, 100-114.	0.6	20
101	Gastrointestinal motility and neurogastroenterology. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 685-697.	1.5	6
102	Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2015, 149, 1399-1407.e2.	1.3	463
103	Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 36-49.	17.8	147
104	Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. <i>Gut</i> , 2015, 64, 84-92.	12.1	167
105	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015, 64, 1774-1782.	12.1	97
106	Interaction between preprandial and postprandial rectal sensory and motor abnormalities in IBS. <i>Gut</i> , 2014, 63, 1441-1449.	12.1	41
107	Self-Reported Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated With More Severe Symptoms and Reduced Quality of Life. <i>American Journal of Gastroenterology</i> , 2013, 108, 634-641.	0.4	469
108	Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls. <i>United European Gastroenterology Journal</i> , 2013, 1, 358-367.	3.8	33

#	ARTICLE	IF	CITATIONS
109	Colonic Transit Time and IBS Symptoms: What's the Link?. American Journal of Gastroenterology, 2012, 107, 754-760.	0.4	144